Results 41 to 50 of about 7,329,727 (241)

Effect of Preoperative Single-Inhaler Triple Therapy on Pulmonary Function in Lung Cancer Patients with Chronic Obstructive Pulmonary Disease and FEV₁ < 1.5 L. [PDF]

Cancers (Basel)
Background/objectives: This study aimed to investigate the impact of single-inhaler triple therapy on selecting treatment for lung cancer and the perioperative period in lung cancer patients with chronic obstructive pulmonary disease (COPD) and a forced ...
Homma T, Saji H, Shimada Y, Tanabe K, Kojima K, Marushima H, Miyazawa T, Kimura H, Sakai H, Otsubo K, Hatakeyama T, Kakizaki N, Tsuchiya T, Morikawa K, Mineshita M.   +14 more
europepmc   +2 more sources

Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial. [PDF]

Int J Chron Obstruct Pulmon Dis, 2022
Andrea Gabrio,1 Necdet B Gunsoy,2 Gianluca Baio,1 Alan Martin,3 Victoria F Paly,4 Nancy Risebrough,5 David MG Halpin,6 Dave Singh,7 Robert A Wise,8 MeiLan K Han,9 Fernando J Martinez,10 Gerard J Criner,11 Neil Martin,12 David A Lipson,13,14 Afisi S ...
Gabrio A, Gunsoy NB, Baio G, Martin A, Paly VF, Risebrough N, Halpin DMG, Singh D, Wise RA, Han MK, Martinez FJ, Criner GJ, Martin N, Lipson DA, Ismaila AS.   +14 more
europepmc   +2 more sources

Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT

Annals of the American Thoracic Society, 2021
Abstract Rationale In the IMPACT (Informing the Pathway of COPD Treatment) trial, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy reduced exacerbation risk versus FF/VI and UMEC/VI and mortality risk versus UMEC/VI.
Mark T. Dransfield, Courtney Crim, Gerard J. Criner, Nicola C. Day, David M. G. Halpin, MeiLan K. Han, C. Elaine Jones, Sally Kilbride, David LaFon, David A. Lipson, David A. Lomas, Neil Martin, Fernando J. Martinez, Dave Singh, Robert A. Wise, Peter Lange   +15 more
openaire   +4 more sources

Effectiveness of Switching from Multiple-Inhaler to Once-Daily Single-Inhaler Triple Therapy in Patients with COPD in a Real-World Setting in Japan. [PDF]

Int J Chron Obstruct Pulmon Dis
Gema Requena,1 Lucinda J Camidge,2 Alexander Ford,2 Masao Yarita,3 Kenichi Hashimoto,4 Thomas Jennison,2 Olivia S Massey,2 Stephen G Noorduyn,5,6 Akiko Mizukami3, † 1Value Evidence and Outcomes, R&D Global Medical, GSK, London, UK; 2Real-World Evidence ...
Requena G, Camidge LJ, Ford A, Yarita M, Hashimoto K, Jennison T, Massey OS, Noorduyn SG, Mizukami A.   +8 more
europepmc   +2 more sources

Triple Therapy of Fluticasone Furoate, Umeclidinium, Vilanterol- A Compelling Choice in Severe Chronic Obstructive Pulmonary Disease [PDF]

Journal of Clinical and Diagnostic Research, 2021
Trelegy Ellipta (GlaxoSmithKlineTM) is the first single inhaler triple combination therapy comprising of umeclidinium, vilanterol and fluticasone approved by the United States Food and Drug Administration (US FDA) for patients with severe COPD in 2019.
B Jagan Nathan, Melina I Sahay, AK Gautham, DK Sriram, Melvin George   +4 more
doaj   +1 more source

Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. [PDF]

, 2013
BACKGROUND: Asthma is characterised by chronic inflammation of the airways and recurrent exacerbations with wheezing, chest tightness and cough. Treatment with inhaled steroids and bronchodilators often results in good control of symptoms, prevention of ...
Mindus, SM, Ferrara, G, Ferrara, G,, Kew, KM, Karner, C   +4 more
core   +1 more source

Open-inhaler versus single-inhaler triple therapy (long-acting muscarinic antagonist, inhaled corticosteroid, and long-acting β₂-agonist) in asthma patients: a narrative review

, 2023
To review the evidence for the use of open-inhaler (inhaled corticosteroid [ICS] plus long-acting β2-agonist [LABA] with separate add-on long-acting muscarinic antagonist [LAMA]) versus single-inhaler triple therapy (ICS/LABA/LAMA combination) and the ...
John J. Oppenheimer (15539549), Michael E. Wechsler (7923218)   +1 more
core   +1 more source

Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety

International Journal of COPD, 2022
Samy Suissa,1,2 Sophie Dell’Aniello,1 Pierre Ernst1,2 1Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital, Montreal, Quebec, Canada; 2Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec ...
Suissa S, Dell'Aniello S, Ernst P
doaj  

Risk of Exacerbation and Pneumonia with Single Inhaler Triple versus Dual Therapie in IMPACT [PDF]

Pneumologie, 2018
Background: To determine overall benefit-risk, we examined the effect of single inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI and FF/VI on the composite outcome of acute exacerbation of COPD or pneumonia in the IMPACT study, a 52-week, randomized, multicentre study in patients with symptomatic COPD and prior ...
Mark Dransfield, Courtney Crim, Gerard Criner, David Halpin, Meilan Han, C. Elaine Jones, Sally Kilbride, Peter Lange, David Lipson, David Lomas, Fernando Martinez, David Singh, Robert Wise   +12 more
openaire   +1 more source

Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation [PDF]

, 2011
Background Although patients have more problems using metered dose inhalers, clinical comparisons suggest they provide similar control to dry powder inhalers.
Eszes, Noemi, Gabriele Nicolini, Chrystyn, Henry, Eszes Noemi, György Losonczy, Noemi Eszes, Henry Chrystyn, Müller, Veronika, Gabriella Gálffy, Chrystyn Henry, Nicolini Gabriele, Gálffy Gabriella, Andrea Bizzi, Lilla Tamási, Bizzi Andrea, Tamási Lilla, Gálffy, Gabriella, Tamási, Lilla, Müller Veronika, Losonczy, György, Nicolini, Gabriele, Bizzi, Andrea, Veronika Müller, Losonczy György   +23 more
core   +2 more sources